Circulating progastrin-releasing peptide in the diagnosis of Small Cell Lung Cancer (SCLC) and in therapeutic monitoring
Open Access
- 7 July 2021
- journal article
- Published by Aboutscience Srl in Journal of Circulating Biomarkers
- Vol. 10, 9-13
- https://doi.org/10.33393/jcb.2021.2212
Abstract
Introduction: Progastrin-releasing peptide (proGRP), a precursor of GRP, has been recently reported as a putative circulating biomarker for differential diagnosis between non–small cell lung cancer (NSCLC) and SCLC. We evaluated the diagnostic effectiveness of proGRP to differentiate patients with NSCLC and SCLC and the usefulness of combined measurement of proGRP and neuron-specific enolase (NSE) for diagnosing SCLC. Methods: Serum proGRP, NSE, cytokeratin 19 fragment 21-1 (CYFRA 21.1), squamous cell carcinoma antigen (SCC Ag) and carcinoembryonic antigen (CEA) were prospectively collected and measured in patients with a new diagnosis of lung cancer. Serum proGRP was also measured in healthy subjects. The serum proGRP, NSE, CYFRA 21.1 and CEA concentrations were determined by an electrochemiluminescence immunoassay and the serum SCC Ag concentration was determined by an automated immunofluorescence assay. Differences between proGRP and NSE in patients with SCLC and NSCLC were evaluated and compared using Mann-Whitney test. Results: A total of 77 patients affected by SCLC (n = 17) and NSCLC (n = 60) were enrolled in the present study. Moreover, 50 cases of healthy subjects were analyzed for proGRP. SCLC patients showed a significantly higher proGRP (1,484 pg/mL; range 168-3,777) levels compared to NSCLC patients (45 pg/mL; range 31.7-60.6), p<0.0001. In healthy subjects the median proGRP level was 36.1 (28.8-43.5) pg/mL, significantly lower than SCLC patients. ProGRP showed a higher specificity when compared to NSE, with a difference in proportion of 47.5% (95% confidence interval 32.5% to 62.5%, p<0.001). Serial measurements of proGRP in SCLC patients showed a decrease in responsive chemotherapy patients.Keywords
This publication has 22 references indexed in Scilit:
- Small cell lung cancer: Where do we go from here?Cancer, 2014
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Diagnostic value of pro-gastrin-releasing peptide for small cell lung cancer: a meta-analysiscclm, 2011
- Comparing the Accuracy of Two Diagnostic TestsPublished by Wiley ,2011
- Plasma proGRP Concentration is Sensitive and Specific for Discriminating Small Cell Lung Cancer from Nonmalignant Conditions or Non-small Cell Lung CancerJournal of Korean Medical Science, 2011
- Tools used in the diagnosis and staging of lung cancer: what's old and what's new?QJM: An International Journal of Medicine, 2009
- Usefulness of Serum Tumor Markers, Including Progastrin-Releasing Peptide, in Patients with Lung Cancer: Correlation with HistologyTumor Biology, 2009
- Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in Monitoring First-Line Chemotherapy of Small Cell Lung CancerClinical Cancer Research, 2008
- Expression of gastrin-releasing peptide receptor gene in developing lung.American Journal of Respiratory Cell and Molecular Biology, 1996
- Human lung small-cell carcinoma contains bombesin.Proceedings of the National Academy of Sciences of the United States of America, 1982